| 발표일자: |
2019년 11월 1일(금)~3(일) |
| 발표번호: |
P(e-poster)-329 |
| 발표장소: |
B3 Parking Area
|
|
|
| 녹내장 안약에 의한 독성 각막 상피병증 환자에서 자가혈청안약 점안의 치료 효과 |
| (1) 서울대학교병원 안과학교실, (2) 서울대학교병원 의생명연구원 인공안구센터 안면역각막재생연구실, (3) 서울대학교병원 조직은행, (4) 서울대학교병원 진단검사의학과 |
| 윤창호 (1, 2), 이현주 (2), 박혜윤 (3), 김형석 (4), 김미금 (1, 2), 정진욱 (1), 오주연 (1, 2) |
|
목적 : To investigate the effects of topical autologous serum (AS) application on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
방법 : The patients who had been using preservative-containing anti-glaucoma eye drops and whose corneal epitheliopathy was refractory to preservative-free artificial tear treatment were prospectively enrolled. The patients topically applied 20% AS to the eye eight times per day for one month. Baseline and one-month changes in symptoms and signs were assessed by the Ocular Surface Disease Index (OSDI) questionnaire, tear break-up time (TBUT), Schirmer I values, corneal staining scores (CSS), corneal sensitivity, InflammaDry® test, and tear cytokine profiles using a bead-based multiplex assay.
결과 : A total of ten consecutive patients were enrolled between January and August 2018, and evaluated after one-month treatment with 20% AS eye drops. Significant improvement was observed in symptoms (OSDI from 25.5±20.9 to 10.5±12.0; P=.039), TBUT (from 3.1±1.8 seconds to 5.4±2.3 seconds; P=.025), CSS (from 7.7±1.8 to 1.8±1.9 NEI scale; P=.005), corneal sensitivity (from 4.6±0.9 cm to 5.8±0.5 cm; P=.013), and metalloproteinase-9 levels (P=.013). There were no significant changes in Schirmer I values and tear cytokine levels. Treatment-related side effects were not detected.
결론 : Topical instillation of 20% AS is an effective treatment for toxic corneal epitheliopathy associated with anti-glaucoma eye drops.
|
| |